Characteristics of high-density lipoprotein subclasses distribution for subjects with desirable total cholesterol levels

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Tian, Li ^a   Long, Shiyin ^b   Fu, Mingde ^a   Liu, Yinghui ^b   Xu, Yanhua ^c   Jia, Lianqun ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Chengdu Hoist Biotechnology Co LTD   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2A; HIGH DENSITY LIPOPROTEIN 2B; HIGH DENSITY LIPOPROTEIN 3A; HIGH DENSITY LIPOPROTEIN 3B; HIGH DENSITY LIPOPROTEIN 3C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRE BETA1 HIGH DENSITY LIPOPROTEIN; PRE BETA2 HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNODETECTION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANALYSIS OF VARIANCE; BLOOD; CLASSIFICATION; MIDDLE AGED;

ADULT; AGED; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 79954991706     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-64     Document Type: Article

References (37)

1. Lipoprotein receptors, plasma cholesterol metabolism, and the regulation of cellular free cholesterol concentration. CJ Fielding, FASEB J 1992 6 3162 3168 1327930
2. Plasma lipoproteins and coronary heart disease. AM Scann, Annals of Clinical and Laboratory Science 1978 8 79 88 205164
3. The primary prevention of myocardial infarction. JE Manson H Tosterson PM Ridker S Satterfield P Hebert O GT JE Buring CH Hennekens, NEJM 1992 326 1406 1416 10.1056/NEJM199205213262107 1533273
4. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. RD Abbott RP Donahue WB Kannel PW Wilson, JAMA 1988 260 3456 3460 10.1001/jama.260.23.3456 2974889 (Pubitemid 19003125)
5. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. DJ Gordon JL Probstfield RJ Garrison JD Neaton WP Castelli JD Knoke DR Jacobs S Bangdiwala HA Tyroler, Circulation 1989 79 8 15 2642759 (Pubitemid 19043669)
6. Prediction of coronary heart disease using risk factor categories. PWF Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel, Circulation 1998 97 1837 1847 9603539 (Pubitemid 28213628)
7. Laboratory assessment of HDL heterogeneity and function. PL Colvin JS Parks, Current opinion in Lipidology 2009 67 7 21
8. Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. LQ Jia SY Long MD Fu BY Yan Y Tian YH Xu LT Gou LT Gou, Metabolism 2006 55 1141 1148 10.1016/j.metabol.2006.04.004 16919530 (Pubitemid 44219052)
9. Alterations of HDL subclasses in endogenous hypertriglyceridemia. LT Gou MD Fu YH Xu Y Tian BY Yan LC Yang, Am Heart J 2005 150 1039 1045 10.1016/j.ahj.2005.02.032 16290993 (Pubitemid 41607795)
10. Relationship between plasma lipid concentrations and HDL subclasses. YY Yang BY Yan MD Fu YH Xu Y Tian, Clin Chim Acta 2005 354 49 58 10.1016/j.cccn.2004.11.015 15748599 (Pubitemid 40320673)
11. Alterations of HDL subclasses in hyperlipidemia. YH Xu MD Fu, Clin Chim Acta 2003 332 95 102 10.1016/S0009-8981(03)00138-4 12763286
12. on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
13. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. GR Warnick T Nguyen AA Albers, Clin Chem 1985 31 217 222 2578337 (Pubitemid 16209717)
14. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. WT Friedewald RI Levy DS Fredrickson, Clin Chem 1972 18 499 502 4337382
15. Immunological assays of apolipoproteins in plasma: methods and instrumentation. C Labeur J Shepherd M Rosseneu, Clin Chem 1990 36 591 597 2182220
16. Immunoassay of human plasma apolipoproteins and clinical applications. BW Liu, Lipoproteins and Atherosclerosis Beijing, People's Health Press, Wang KQ, 1995 359 368
17. Study on the immunodetection method of HDL subclasses in human serum. XW Wu MD Fu BW Liu, Chin J Arterioscler 1999 7 253 255
18. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. J Stamler ML Daviglus DB Garside AR Dyer P Greenland JD Neaton, JAMA 2000 284 311 318 10.1001/jama.284.3.311 10891962 (Pubitemid 30469857)
19. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Multiple Risk Factor Intervention Trial Research Group. JD Neaton D Wentworth, Arch Intern Med 1992 152 56 64 10.1001/archinte.152.1.56 1728930
20. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. WM Verschuren DR Jacobs BP Bloemberg D Kromhout A Menotti C Aravanis H Blackburn R Buzina AS Dontas F Fidanza, JAMA 1995 274 131 136 10.1001/jama.274.2.131 7596000
21. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. AR Sharrett CM Ballantyne SA Coady G Heiss PD Sorlie D Catellier W Patsch, Circulation 2001 104 1108 1113 10.1161/hc3501.095214 11535564 (Pubitemid 32830392)
22. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? MR Law NJ Wald SG Thompson, BMJ 1994 308 367 372 8043072 (Pubitemid 24078498)
23. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. WE Boden, Am J Cardiol 2000 86 19L 22L 11374850
24. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. BF Asztalos LA Cupples S Demissie KV Horvath CE Cox MC Batista EJ Schaefer, Arterioscler Thromb Vasc Biol 2004 24 2181 2187 10.1161/01.ATV.0000146325.93749.a8 15388521 (Pubitemid 39482449)
25. Pro-inflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. M McMahon J Grossman J FitzGerald E Dahlin-Lee DJ Wallace BY Thong H Badsha K Kalunian C Charles M Navab AM Fogelman BH Hahn, Arthritis Rheum 2006 54 2541 2549 10.1002/art.21976 16868975 (Pubitemid 44205015)
26. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. JD Otvos D Collins DS Freedman I Shalaurova EJ Schaefer JR McNamara HE Bloomfield SJ Rovins, Circulation 2006 113 1556 1563 10.1161/CIRCULATIONAHA.105.565135 16534013 (Pubitemid 43739414)
27. Cholesterol profile measurement by vertical auto profile method. KR Kulkarni, Clinics Lab Med, Smith DA, 2006 26 787 802 10.1016/j.cll.2006.07.004 (Pubitemid 44724932)
28. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. M Okazaki S Usui A Fukui I Kubota H Tomoike, Clin Chem 2006 52 2049 2053 10.1373/clinchem.2006.070094 16990425 (Pubitemid 44658206)
29. Prebeta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. S Hirayama T Miida O Miyazaki Y Aizawa, Diabetes Care 2007 30 1289 1291 10.2337/dc06-1948 17303789 (Pubitemid 46684667)
30. Role of apoA-I, ABCA1, LCAT and SR-BI in the biogenesis of HDL. VI Zannis A Chroni M Krieger, J Mol Med 2006 84 276 294 10.1007/s00109-005-0030-4 16501936
31. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? EJ Schaefer BF Asztalos, Curr Opin Cardiol 2007 22 373 378 10.1097/HCO.0b013e3281fbd3c7 17556892 (Pubitemid 46897291)
32. Remaley AT, MD, PhD, is a member of the senior staff of the Department of Laboratory Medicine at the National Institutes of Health (Bethesda, Md.) and is the Section Chief of the Lipoprotein Metabolism Laboratory at the National, Heart, Lung and Blood Institute. He has served on the FDA's Chemistry and Clinical Toxicology Panel since 2002.
33. Influence of cholesterol status on blood lipid and lipoprotein enzyme responses to aerobic exercise. PW Grandjean SF Crouse J James Rocks, J Appl Physiol 2000 89 472 480 10926628 (Pubitemid 30637092)
34. Remodeling of high density lipoproteins by plasma factors. KA Rye MA Clay PJ Barter, Atherosclerosis 1999 145 227 238 10.1016/S0021-9150(99)00150-1 10488948 (Pubitemid 29359129)
35. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. WP Castelli RJ Garrison PWF Wilson RD Abbott S Kalousdian WB Kannel, JAMA 1986 256 2835 2838 10.1001/jama.256.20.2835 3773200 (Pubitemid 17178361)
36. Study on the pathogenesis of endogenous hypoertriglyceridemia. BW Liu, Chin J Arterioscler 1993 1 67 69
37. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. F Tato GL Vega AR Tall, Arterioscler Thromb Vasc Biol 1995 15 112 120 7749806